Support: This podcast was funded by GSK.
Disclaimer: The opinions expressed in this podcast belong solely to the named interviewees. The speakers received honoraria for participating in this recording.
Disclosures: Harrison has received research funding from GSK, Incyte, and Novartis; and been an advisor for BMS, Calitryx, Novartis, Galacteo, Geron, Gilead, GSK, Incyte, Ionis, Janssen, Kartos, Karyopharm, Merck, Menarini Stemline, Keros, Takeda, Silence, Sumitomo, Syntara, and SOBI. Palandri has received honoraria and/or been an advisor or consultant for Amgen, AOP, BMS, Grifols, GSK, Incyte, Novartis, Sanofi, Sobi, and Takeda. Bose has received funding from Incyte, BMS, GSK, Novartis, Merck, Ionis, Disc, Sumitomo, Karyopharm, Geron, Janssen, Kartos, Telios, Ajax, Blueprint, and Cogent; and been an advisor or consultant for Incyte, BMS, GSK, Sobi, Novartis, Merck, Takeda, Geron, Ionis, Deciphera, Disc, Sumitomo, Karyopharm, Blueprint, Cogent, Abbvie, Pharma Essentia, Vyne, V6, Damora, Morphic, Jubilant, and Raythera.
Join leading myeloproliferative neoplasm (MPN) experts Claire Harrison, Francesca Palandri, and Prithviraj Bose as they discuss the most important myelofibrosis (MF) and MPN data presented at the European Hematology Association (EHA) 2026 Congress. Moderated by Jessica Jinks, this expert panel explores the latest post-hoc analyses of JAK inhibitor therapies, including new insights into momelotinib, ruxolitinib, and strategies for treatment sequencing and patient selection.
Moderator:
Jessica Jinks1
Speakers:
Claire Harrison2
Francesca Palandri3
Prithviraj Bose4
1. EMJ, London, UK
2. Guy’s and St Thomas’ NHS Foundation Trust, London, UK
3. IRCCS Azienda Ospedaliero Universitaria di Bologna, University of Bologna, Italy
4. University of Texas MD Anderson Cancer Center, Houston, USA
